Study at a glance
How might vitamin D affect the release of iron from cells?
This page brings together laboratory experiments and small human studies of vitamin D and iron control. Hepcidin is a hormone that reduces the release of iron from cells. It acts on ferroportin, a protein that allows iron to leave cells. Lower hepcidin may therefore make stored and recycled iron more available.
What did laboratory experiments find about vitamin D and iron release?
In human liver and immune cells grown in the laboratory, vitamin D reduced activity of the gene that makes hepcidin by about half. Tests supported a direct effect through the vitamin D receptor, which receives vitamin D signals inside cells. Ferroportin protein increased. These findings show a possible way for vitamin D to influence iron release.
How did vitamin D affect hepcidin in people?
In a small study of healthy volunteers, a single 100,000 IU dose of vitamin D2 was followed by about 34% lower blood hepcidin within 24 hours. A later trial randomly assigned 28 healthy adults to a single 250,000 IU dose of vitamin D3 or an inactive treatment. After one week, hepcidin had fallen about 73% from its starting value in the vitamin D group and was significantly lower than in the comparison group. These were research doses, not instructions for personal use.
Does lower hepcidin prove that vitamin D improves anaemia?
In the later trial, ferritin, a measure related to iron stores, and the measured signs of inflammation did not change significantly. Lower hepcidin does not prove that more red blood cells were produced or that anaemia improved. Other studies have found no benefit or results that depend on the population. Vitamin D is one influence on iron control; this evidence does not establish it as a replacement for investigating or treating iron deficiency or anaemia.
Read the full article below ↓Iron availability is controlled not only by how much iron enters the body but also by whether stored and recycled iron can move between cells and the circulation. Hepcidin is central to that control. When hepcidin rises, it binds to the iron exporter ferroportin and reduces iron release from intestinal cells, macrophages and other iron-handling tissues. When hepcidin falls, ferroportin-mediated iron export becomes more available. Experimental and human evidence indicates that vitamin D signalling can interact directly with this hepcidin-ferroportin system, creating a mechanistic connection between vitamin D physiology and Vitamin D and Iron Metabolism. The evidence does not mean vitamin D supplementation is an iron treatment in every person, but it does show that vitamin D can participate in regulation of the machinery governing iron mobilisation. For a shorter version of this evidence review, see Vitamin D Regulation of Hepcidin, Ferroportin and Iron Mobilisation: Study Summary.
Hepcidin controls whether iron remains trapped or becomes available
Hepcidin is a peptide hormone produced predominantly by the liver. Its physiological importance comes from its interaction with ferroportin, the major cellular iron exporter. Ferroportin allows iron to leave enterocytes after intestinal absorption and permits macrophages to return iron recovered from ageing red blood cells to the circulation. Hepcidin binding causes ferroportin to be internalised and degraded, reducing iron export.
This creates an important distinction between total body iron and circulating iron availability. A person can possess substantial iron stores while iron is functionally restricted because elevated hepcidin reduces access to those stores. Ferritin may therefore behave very differently from serum iron or transferrin saturation, particularly during inflammation. That is one reason single laboratory measurements need physiological context, a broader principle developed in What Vitamin D Levels Represent.
Hepcidin is itself regulated by several inputs. Iron loading tends to increase it. Increased erythropoietic demand tends to suppress it. Inflammation, particularly signalling involving interleukin-6, can increase hepcidin and restrict circulating iron. The inflammatory branch is therefore particularly relevant to Vitamin D and Inflammatory Signalling and to the development of anaemia of inflammation.
Vitamin D can suppress HAMP transcription
Bacchetta and colleagues investigated whether vitamin D could regulate the gene encoding hepcidin, HAMP. Their work combined human cell experiments with a small human supplementation study. In cultured hepatocytes and monocytes, treatment with either 25-hydroxyvitamin D [25(OH)D] or active 1,25-dihydroxyvitamin D [1,25(OH)₂D] reduced HAMP messenger RNA expression by approximately half.
The mechanistic experiments went further than observing an association. Promoter-reporter and chromatin-immunoprecipitation analyses supported direct transcriptional regulation involving the vitamin D receptor. Liganded VDR interacted with the HAMP promoter environment, and 1,25(OH)₂D reduced HAMP transcription. The direction differed from familiar vitamin-D-induced antimicrobial genes such as CAMP, demonstrating that VDR signalling can activate some transcriptional programmes while repressing others.
This is relevant to Vitamin D and Transcription Factors because the iron effect is not simply a downstream consequence of changing vitamin D blood levels. It involves transcriptional control of an iron-regulatory hormone. It is also consistent with the wider signalling architecture described in Vitamin D Receptors.
Suppressing hepcidin changes ferroportin biology
The cellular experiments showed a corresponding increase in ferroportin protein when HAMP expression was suppressed. Ferritin expression within cells also fell. This sequence gives the mechanism physiological coherence: lower hepcidin reduces the signal that normally limits ferroportin, allowing greater potential for cellular iron export rather than merely changing a gene without an iron-handling consequence.
That mechanism matters particularly in macrophages. A large proportion of iron required for daily erythropoiesis comes not from newly absorbed dietary iron but from macrophage recycling of iron recovered from senescent red blood cells. A pathway that changes hepcidin-ferroportin regulation therefore has the potential to alter iron availability without changing total body iron stores.
This does not imply that vitamin D is the dominant controller of ferroportin in every physiological condition. Iron status, erythropoietic demand, renal physiology and inflammatory signalling can all exert powerful effects. Vitamin D should therefore be treated as one regulator within the iron-control network rather than as an overriding switch.
A human pilot study showed a rapid fall in circulating hepcidin
The same research programme included healthy volunteers who received a single oral dose of 100,000 IU vitamin D₂. Mean circulating 25(OH)D increased from approximately 27 ng/mL before supplementation to 44 ng/mL afterwards. Within 24 hours, circulating hepcidin had fallen by approximately 34%.
The rapid timing is useful because it is compatible with a regulatory response rather than a slow correction of iron stores. The result does not prove that iron delivery to the bone marrow increased sufficiently to change haemoglobin, because those downstream endpoints were not established by this short experiment. It demonstrates that changing vitamin D exposure can be followed rapidly by a measurable change in an iron-regulatory hormone.
The distinction between a mechanistic biomarker and a clinically meaningful downstream effect is central to Vitamin D Status vs Vitamin D Effect. A fall in hepcidin may alter the regulatory environment, but whether haemoglobin, iron stores or symptoms change depends on what limits erythropoiesis in the individual.
A randomized high-dose trial reproduced hepcidin suppression
A later pilot randomized, double-blind, placebo-controlled trial tested a single 250,000 IU dose of vitamin D₃ in 28 healthy adults. More than 70% of participants were vitamin D deficient at baseline. One week after dosing, plasma hepcidin had fallen by approximately 73% from baseline in the vitamin-D group. The placebo group did not show a statistically significant change.
The between-group comparison at one week was also significant, with geometric mean hepcidin concentrations of approximately 2.4 ng/mL in the vitamin-D group and 9.0 ng/mL in placebo. This strengthens the argument that the earlier observation was not merely a transient uncontrolled association.
However, ferritin did not change significantly. Neither did the measured inflammatory cytokines IL-1β, IL-6, IL-8 or MCP-1. This is scientifically useful because it separates several possible mechanisms. Hepcidin suppression occurred without detectable short-term reduction in those measured inflammatory markers and without measurable depletion of ferritin stores.
Direct hepcidin regulation can be separated from general anti-inflammatory effects
Inflammation is a major hepcidin stimulus, so one possible explanation for lower hepcidin after vitamin D would be that vitamin D first reduced inflammation and hepcidin then fell secondarily. The randomized healthy-adult study did not support that simple sequence over one week because hepcidin changed while the measured cytokines did not.
That does not mean inflammation is irrelevant. In chronic inflammatory disease, vitamin D, cytokines and hepcidin can interact simultaneously. Rather, the trial suggests that vitamin D-mediated hepcidin regulation is not necessarily dependent on a preceding measurable fall in systemic inflammatory cytokines. The inflammatory pathway remains an additional layer, particularly in the territory covered by Vitamin D and Chronic Inflammation.
25(OH)D and 1,25(OH)₂D perform different evidential roles
Interpretation also requires care over which vitamin D metabolite is being discussed. Routine vitamin D status is generally assessed with circulating 25(OH)D. The transcriptional mechanism, however, is mediated through active vitamin-D signalling involving VDR and 1,25(OH)₂D. Cells capable of local activation may therefore experience signalling conditions that are not represented perfectly by a single circulating 25(OH)D value.
This distinction is developed in Vitamin D Testing: 25-OH-D vs 1,25-OH₂-D. The iron evidence should not be interpreted as though a particular 25(OH)D concentration automatically predicts a fixed amount of hepcidin suppression.
Why reduced hepcidin does not guarantee correction of anaemia
Haemoglobin production depends on more than iron release. Bone-marrow function, erythropoietin, renal function, inflammation, actual iron stores, folate and vitamin B12 status, blood loss and many disease-specific factors can determine whether additional available iron becomes new red-cell mass.
Consequently, hepcidin suppression is a mechanistically important intermediate endpoint rather than proof that vitamin D supplementation will correct anaemia. Later intervention studies in chronic kidney disease and older populations have produced null or context-dependent results for haemoglobin and iron biomarkers. Those findings do not invalidate the hepcidin mechanism; they define its physiological limits.
The broader pattern is consistent with Vitamin D Response: a real molecular response can occur without producing the same whole-body outcome in every population. Disease state can alter what step in the pathway is actually limiting.
What this evidence establishes
The strongest conclusion is that vitamin D signalling can regulate the hepcidin-ferroportin axis. Experimental evidence supports direct repression of HAMP transcription through VDR-related mechanisms. Lower HAMP expression is associated with greater ferroportin protein. Human supplementation studies show rapid reductions in circulating hepcidin after high-dose vitamin D exposure.
The evidence does not establish that vitamin D is universally capable of mobilising enough iron to improve haemoglobin, that vitamin D deficiency is a primary cause of iron deficiency, or that supplementation should replace investigation and treatment of established iron deficiency or anaemia.
For the integration of this mechanism with inflammatory anaemia and the contrasting clinical-trial evidence, see Vitamin D, Hepcidin, Iron Availability and Anaemia: Evidence Synthesis.
Scientific sources
Adriana Bacchetta and colleagues. Suppression of iron-regulatory hepcidin by vitamin D. Journal of the American Society of Nephrology. PMID: 24204002.
Jessica A Alvarez and colleagues. High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults. Clinical Nutrition. PMID: 27402475.
Related reading
Antenatal iron supplementation, FGF23, and bone metabolism in Kenyan women and their offspring: secondary analysis of a randomized controlled trial
We aimed to determine the effect of antenatal oral iron supplementation on FGF23 concentration and maternal and infant markers of bone-mineral regulation.
Original paper ↗Read more →Vitamin D Regulation of Hepcidin, Ferroportin and Iron Mobilisation: Study Summary
A concise review of evidence linking vitamin D signalling with hepcidin suppression, ferroportin regulation and iron availability.
Read more →Vitamin D, Hepcidin, Iron Availability and Anaemia: Evidence Synthesis
Evidence synthesis integrating vitamin D, hepcidin, ferroportin, inflammation, iron availability and anaemia across mechanistic and clinical studies.
Read more →Intact FGF23 and Markers of Iron Homeostasis, Inflammation, and Bone Mineral Metabolism in Acute Pediatric Infections
The aim of this prospective clinical study is to evaluate the association of i-FGF23 with hepcidin and markers of iron homeostasis, erythropoiesis, inflammation, and bone mineral metabolism in acute pediatric infections.
Original paper ↗Read more →The Effect of Vitamin D Supplementation on Hepcidin, Iron Status, and Inflammation in Pregnant Women in the United Kingdom
Our aim was to identify whether antenatal vitamin D3 supplementation affects iron status (via hepcidin suppression) and/or inflammation.
Original paper ↗Read more →1,25(OH)2D3 Inhibited Ferroptosis in Zebrafish Liver Cells (ZFL) by Regulating Keap1-Nrf2-GPx4 and NF-κB-hepcidin Axis
Ferroptosis is a kind of iron-dependent programed cell death.
Original paper ↗Read more →Alterations in regulators of the renal-bone axis, inflammation and iron status in older people with early renal impairment and the effect of vitamin D supplementation
Markers of the renal-bone axis, inflammation and iron status were investigated pre: and post-supplementation.
Original paper ↗Read more →Effects of a second iron-dextran injection administered to piglets during lactation on differential gene expression in liver and duodenum at weaning
Six female littermate piglets were used in an experiment to evaluate the mRNA expression in tissues from piglets given one or two 1 mL injections of iron dextran (200 mg Fe/mL).
Original paper ↗Read more →High ferritin is associated with liver and bone marrow iron accumulation: Effects of 1-year deferoxamine treatment in hemodialysis-associated iron overload
Iron (Fe) supplementation is a critical component of anemia therapy for patients with chronic kidney disease (CKD).
Original paper ↗Read more →Multiple Indicators of Undernutrition, Infection, and Inflammation in Lactating Women Are Associated with Maternal Iron Status and Infant Anthropometry in Panama: The MINDI Cohort
Maternal infections, nutrient deficiencies, and inflammation (MINDI) co-exist in lactating indigenous women in Panama, but their impact on maternal iron status and infant growth is unknown.
Original paper ↗Read more →Multiple Infections, Nutrient Deficiencies, and Inflammation as Determinants of Anemia and Iron Status during Pregnancy: The MINDI Cohort
In pregnant women with multiple infections, nutrient deficiencies, and inflammation (MINDI), the study of anemia and iron status is limited.
Original paper ↗Read more →Vitamin D, Inflammation and Anaemia-Related Iron Restriction: Full Study
Evidence linking vitamin D status with inflammation, hepcidin, iron restriction and haemoglobin in inflammatory disease.
Read more →Vitamin D, Inflammation and Anaemia-Related Iron Restriction: Study Summary
A concise review of vitamin D, inflammatory hepcidin signalling, iron restriction and anaemia-related physiology.
Read more →Assessment of Vitamin D status and association with inflammation: Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project
We examined correlations between inflammation biomarkers, CRP or alpha-1-acid glycoprotein (AGP), and serum 25(OH)D concentrations among preschool children (PSC; 6 to 59 mo) and nonpregnant females of reproductive age (FRA; 15 to 49 y).
Original paper ↗Read more →25(OH) D3 alleviate liver NK cytotoxicity in acute but not in chronic fibrosis model of BALB/c mice due to modulations in vitamin D receptor
In this study, we aimed to evaluate changes in liver NK cells cytotoxicity due to modulations in VDR in CCl4 fibrosis model following 25(OH) D3 injections.
Original paper ↗Read more →A comparative study of the injury patterns and inflammatory response between suicidal and unintentional falls from height in Germany
This study aims to analyse injury patterns, inflammatory responses and complication rates in people who have jumped to their death, compared to those who have fallen unintentionally.
Original paper ↗Read more →An Inflammation-Adjusted Framework for Nutritional Assessment in Multimorbid Patients with Advanced Neurological Diseases
Background and Objectives: Laboratory parameters associated with nutritional and metabolic status may be substantially influenced by inflammatory activity, complicating their interpretation in patients with advanced neurological diseases.
Original paper ↗Read more →Association of Bone Mass, Falls, and Vertebral Fractures in Older Patients on Hemodialysis: The Role of Comprehensive Geriatric Assessment
Participants had multiple comorbidities, typical of this population, including anemia, cardiovascular disease and chronic liver disease.
Original paper ↗Read more →Prognostic significance of vitamin D receptor (VDR) gene polymorphisms in liver cirrhosis
Here, we investigated the association between BsmI, ApaI, TaqI and FokI VDR polymorphisms and the severity of liver cirrhosis in relation to serum cytokine and lipopolysaccharide binding protein (LBP) levels and their role on survival in cirrhotic patients.
Original paper ↗Read more →Vitamin D Genetics Beyond Serum 25(OH)D: VDR rs2228570 (FokI) Polymorphism, Inflammation, and Quality of Life in Orthopedic Patients
This study investigated the rs2228570 (FokI) variant in relation to inflammatory, hematologic, and patient-reported outcomes in orthopedic patients.
Original paper ↗Read more →Vitamin D receptor ApaI polymorphism associated with progression of liver disease in Vietnamese patients chronically infected with hepatitis B virus
In the recessive model, the genotype ApaI AA was found more frequently among HCC compared to CHB patients (OR = 2.56, 95%CI = 1.01 to 6.48, P = 0.04).
Original paper ↗Read more →Original sources
Suppression of iron-regulatory hepcidin by vitamin D
Adriana Bacchetta and colleagues.
Publication details
Adriana Bacchetta and colleagues. Suppression of iron-regulatory hepcidin by vitamin D. Journal of the American Society of Nephrology. PMID: 24204002.
High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults
Jessica A Alvarez and colleagues.
Publication details
Jessica A Alvarez and colleagues. High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults. Clinical Nutrition. PMID: 27402475.